NO327798B1 - Krystallinske former av natriumsaltet av 5-klor-2-metoksy-N-(2-(4-metoksy-3-metylaminotio-karbonylamino-sulfonylfenyl)etyl)benzamid, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytiske preparater omfattende disse - Google Patents

Krystallinske former av natriumsaltet av 5-klor-2-metoksy-N-(2-(4-metoksy-3-metylaminotio-karbonylamino-sulfonylfenyl)etyl)benzamid, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytiske preparater omfattende disse Download PDF

Info

Publication number: NO327798B1
Authority: NO; Norway
Prior art keywords: methoxy; benzamide; sodium salt; chloro; ethyl
Prior art date: 1999-04-16

Application number

NO20015014A

Other languages

English (en)

Norwegian (no)

Other versions

NO20015014D0 (no

NO20015014L (no

Inventor

Heinrich Englert

Uwe Gerlach

Tobias Metzenthin

Harald Schneider

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-16

Filing date

2001-10-15

Publication date

2009-09-28

2001-10-15 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2001-10-15 Publication of NO20015014D0 publication Critical patent/NO20015014D0/no

2001-10-15 Publication of NO20015014L publication Critical patent/NO20015014L/no

2009-09-28 Publication of NO327798B1 publication Critical patent/NO327798B1/no

Links

159000000000 sodium salts Chemical class 0.000 title claims description 128
238000000034 method Methods 0.000 title claims description 37
238000002360 preparation method Methods 0.000 title claims description 33
230000008569 process Effects 0.000 title claims description 14
239000008194 pharmaceutical composition Substances 0.000 title description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 216
239000013078 crystal Substances 0.000 claims description 115
230000004048 modification Effects 0.000 claims description 114
238000012986 modification Methods 0.000 claims description 114
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 92
VXTKXGKPBOLHRY-UHFFFAOYSA-N 5-chloro-2-methoxy-n-[2-[4-methoxy-3-(methylcarbamothioylsulfamoyl)phenyl]ethyl]benzamide Chemical compound C1=C(OC)C(S(=O)(=O)NC(=S)NC)=CC(CCNC(=O)C=2C(=CC=C(Cl)C=2)OC)=C1 VXTKXGKPBOLHRY-UHFFFAOYSA-N 0.000 claims description 57
239000000203 mixture Substances 0.000 claims description 57
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 55
238000006243 chemical reaction Methods 0.000 claims description 45
239000002904 solvent Substances 0.000 claims description 33
150000003388 sodium compounds Chemical class 0.000 claims description 30
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 26
239000000825 pharmaceutical preparation Substances 0.000 claims description 22
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 21
238000010438 heat treatment Methods 0.000 claims description 16
238000002441 X-ray diffraction Methods 0.000 claims description 15
206010003119 arrhythmia Diseases 0.000 claims description 13
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 13
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 12
238000011282 treatment Methods 0.000 claims description 12
206010049418 Sudden Cardiac Death Diseases 0.000 claims description 10
238000010586 diagram Methods 0.000 claims description 10
230000002265 prevention Effects 0.000 claims description 10
230000005855 radiation Effects 0.000 claims description 10
102000016924 KATP Channels Human genes 0.000 claims description 9
108010053914 KATP Channels Proteins 0.000 claims description 9
239000003937 drug carrier Substances 0.000 claims description 9
239000003814 drug Substances 0.000 claims description 8
238000011321 prophylaxis Methods 0.000 claims description 8
230000000302 ischemic effect Effects 0.000 claims description 7
239000008177 pharmaceutical agent Substances 0.000 claims description 7
230000002401 inhibitory effect Effects 0.000 claims description 6
230000002107 myocardial effect Effects 0.000 claims description 5
-1 5-chloro-2-methoxy-N-(2-(5-methoxy-3-methylaminothiocarbonylaminosulfonyl-phenyl)ethyl)benzamide Chemical compound 0.000 claims description 4
230000004217 heart function Effects 0.000 claims description 4
230000001771 impaired effect Effects 0.000 claims description 4
238000002054 transplantation Methods 0.000 claims description 4
238000012545 processing Methods 0.000 claims description 3
229940079593 drug Drugs 0.000 claims description 2
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 154
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
239000000243 solution Substances 0.000 description 26
150000001875 compounds Chemical class 0.000 description 16
238000004519 manufacturing process Methods 0.000 description 16
150000003839 salts Chemical class 0.000 description 15
239000000126 substance Substances 0.000 description 14
238000002955 isolation Methods 0.000 description 12
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 11
239000000047 product Substances 0.000 description 11
239000007787 solid Substances 0.000 description 11
239000000725 suspension Substances 0.000 description 11
239000011877 solvent mixture Substances 0.000 description 10
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
238000001914 filtration Methods 0.000 description 8
239000007858 starting material Substances 0.000 description 8
238000003756 stirring Methods 0.000 description 8
238000009835 boiling Methods 0.000 description 7
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000011734 sodium Substances 0.000 description 6
229910052708 sodium Inorganic materials 0.000 description 6
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
150000001298 alcohols Chemical class 0.000 description 5
230000006793 arrhythmia Effects 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 5
230000009466 transformation Effects 0.000 description 5
CQSPCVKAOKHVGQ-UHFFFAOYSA-N 5-chloro-2-methoxy-n-[2-[4-methoxy-3-(methylcarbamothioyl)-2-sulfamoylphenyl]ethyl]benzamide Chemical compound CNC(=S)C1=C(OC)C=CC(CCNC(=O)C=2C(=CC=C(Cl)C=2)OC)=C1S(N)(=O)=O CQSPCVKAOKHVGQ-UHFFFAOYSA-N 0.000 description 4
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
LGDSHSYDSCRFAB-UHFFFAOYSA-N Methyl isothiocyanate Chemical compound CN=C=S LGDSHSYDSCRFAB-UHFFFAOYSA-N 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
206010019280 Heart failures Diseases 0.000 description 3
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 3
230000008901 benefit Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000004413 cardiac myocyte Anatomy 0.000 description 3
239000000969 carrier Substances 0.000 description 3
150000001768 cations Chemical class 0.000 description 3
238000001816 cooling Methods 0.000 description 3
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
201000010099 disease Diseases 0.000 description 3
238000004821 distillation Methods 0.000 description 3
238000001035 drying Methods 0.000 description 3
239000011521 glass Substances 0.000 description 3
238000001802 infusion Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000012312 sodium hydride Substances 0.000 description 3
229910000104 sodium hydride Inorganic materials 0.000 description 3
229910001415 sodium ion Inorganic materials 0.000 description 3
239000003826 tablet Substances 0.000 description 3
LTPVSOCPYWDIFU-UHFFFAOYSA-N 4-methoxyphenylethylamine Chemical compound COC1=CC=C(CCN)C=C1 LTPVSOCPYWDIFU-UHFFFAOYSA-N 0.000 description 2
PMXIRRHDWBILHD-UHFFFAOYSA-N 5-chloro-2-methoxy-n-[2-(4-methoxy-3-sulfamoylphenyl)ethyl]benzamide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(OC)C(S(N)(=O)=O)=C1 PMXIRRHDWBILHD-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
102000004257 Potassium Channel Human genes 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
206010042600 Supraventricular arrhythmias Diseases 0.000 description 2
230000036982 action potential Effects 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
150000002170 ethers Chemical class 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910021645 metal ion Inorganic materials 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
108020001213 potassium channel Proteins 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea group Chemical group NC(=S)N UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
208000003663 ventricular fibrillation Diseases 0.000 description 2
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
WCJRHGNHYGWFCU-UHFFFAOYSA-N 5-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]-2-methoxybenzenesulfonyl chloride Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(OC)C(S(Cl)(=O)=O)=C1 WCJRHGNHYGWFCU-UHFFFAOYSA-N 0.000 description 1
GZWLQWBJRJSDBR-UHFFFAOYSA-N 5-chloro-2-methoxy-n-[2-(4-methoxyphenyl)ethyl]benzamide Chemical compound C1=CC(OC)=CC=C1CCNC(=O)C1=CC(Cl)=CC=C1OC GZWLQWBJRJSDBR-UHFFFAOYSA-N 0.000 description 1
JVLUMHRASWENRU-UHFFFAOYSA-N 5-chloro-2-methoxybenzoyl chloride Chemical compound COC1=CC=C(Cl)C=C1C(Cl)=O JVLUMHRASWENRU-UHFFFAOYSA-N 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
206010007572 Cardiac hypertrophy Diseases 0.000 description 1
208000006029 Cardiomegaly Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229940100389 Sulfonylurea Drugs 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
206010047281 Ventricular arrhythmia Diseases 0.000 description 1
206010047289 Ventricular extrasystoles Diseases 0.000 description 1
YSVZGWAJIHWNQK-UHFFFAOYSA-N [3-(hydroxymethyl)-2-bicyclo[2.2.1]heptanyl]methanol Chemical compound C1CC2C(CO)C(CO)C1C2 YSVZGWAJIHWNQK-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
150000004703 alkoxides Chemical class 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
230000003440 anti-fibrillation Effects 0.000 description 1
239000003416 antiarrhythmic agent Substances 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000002763 arrhythmic effect Effects 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
235000019445 benzyl alcohol Nutrition 0.000 description 1
150000003938 benzyl alcohols Chemical class 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
206010061592 cardiac fibrillation Diseases 0.000 description 1
239000008148 cardioplegic solution Substances 0.000 description 1
230000005792 cardiovascular activity Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000006735 deficit Effects 0.000 description 1
210000003298 dental enamel Anatomy 0.000 description 1
230000005595 deprotonation Effects 0.000 description 1
238000010537 deprotonation reaction Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
230000003804 effect on potassium Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000004744 fabric Substances 0.000 description 1
230000002600 fibrillogenic effect Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910001425 magnesium ion Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007721 medicinal effect Effects 0.000 description 1
230000028161 membrane depolarization Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
MHCZCXVHMISMQD-UHFFFAOYSA-N n-[2-[2-(carbamothioylsulfamoyl)-4-methoxy-3-methylphenyl]ethyl]-5-chloro-2-methoxybenzamide Chemical compound NC(=S)NS(=O)(=O)C1=C(C)C(OC)=CC=C1CCNC(=O)C1=CC(Cl)=CC=C1OC MHCZCXVHMISMQD-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
239000012454 non-polar solvent Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
150000002891 organic anions Chemical class 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000001314 paroxysmal effect Effects 0.000 description 1
239000006072 paste Substances 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000003495 polar organic solvent Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
238000000746 purification Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000004904 shortening Methods 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000011146 sterile filtration Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000004441 surface measurement Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
206010047302 ventricular tachycardia Diseases 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
238000010626 work up procedure Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/40—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of thiourea or isothiourea groups further bound to other hetero atoms
- C07C335/42—Sulfonylthioureas; Sulfonylisothioureas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Surgery (AREA)
Hospice & Palliative Care (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20015014A 1999-04-16 2001-10-15 Krystallinske former av natriumsaltet av 5-klor-2-metoksy-N-(2-(4-metoksy-3-metylaminotio-karbonylamino-sulfonylfenyl)etyl)benzamid, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytiske preparater omfattende disse NO327798B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19917233A DE19917233A1 (de)	1999-04-16	1999-04-16	Kristalline Formen des Natriumsalzes des 5-Chlor-2-methoxy-N-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonyl-phenyl)-ethyl)- benzamids
PCT/EP2000/002984 WO2000063167A1 (en)	1999-04-16	2000-04-04	Crystalline forms of the sodium salt of 5- chloro -2- methoxy -n- (2- (4-methoxy -3- methyl aminothio carbonylamino sulfonylphenyl) ethyl) benzamide

Publications (3)

Publication Number	Publication Date
NO20015014D0 NO20015014D0 (no)	2001-10-15
NO20015014L NO20015014L (no)	2001-10-15
NO327798B1 true NO327798B1 (no)	2009-09-28

Family

ID=7904803

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20015014A NO327798B1 (no)	1999-04-16	2001-10-15	Krystallinske former av natriumsaltet av 5-klor-2-metoksy-N-(2-(4-metoksy-3-metylaminotio-karbonylamino-sulfonylfenyl)etyl)benzamid, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytiske preparater omfattende disse

Country Status (33)

Country	Link
US (1)	US6723751B1 (he)
EP (2)	EP1637519B1 (he)
JP (1)	JP4662640B2 (he)
KR (1)	KR100700302B1 (he)
CN (1)	CN1168712C (he)
AR (1)	AR023479A1 (he)
AT (2)	ATE311364T1 (he)
AU (1)	AU773246B2 (he)
BR (1)	BR0010658A (he)
CA (1)	CA2370388C (he)
CZ (1)	CZ302459B6 (he)
DE (3)	DE19917233A1 (he)
DK (1)	DK1173418T3 (he)
EE (1)	EE04612B1 (he)
ES (1)	ES2251996T3 (he)
HK (1)	HK1046270B (he)
HR (1)	HRP20010744B1 (he)
HU (1)	HU229082B1 (he)
IL (2)	IL145921A0 (he)
ME (1)	MEP55708A (he)
MX (1)	MXPA01010275A (he)
MY (1)	MY122588A (he)
NO (1)	NO327798B1 (he)
NZ (1)	NZ514788A (he)
PL (1)	PL203809B1 (he)
RS (1)	RS50916B (he)
RU (1)	RU2235089C2 (he)
SI (1)	SI1173418T1 (he)
SK (1)	SK287175B6 (he)
TR (2)	TR200501142T2 (he)
TW (1)	TWI276622B (he)
WO (1)	WO2000063167A1 (he)
ZA (1)	ZA200108400B (he)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20080008440A (ko) *	2003-03-17	2008-01-23	니뽄 다바코 산교 가부시키가이샤	Ｃｅｔｐ 억제제의 약제학적 조성물
TWI494102B (zh) *	2003-05-02	2015-08-01	Japan Tobacco Inc	包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0612724T3 (da) *	1993-02-23	1997-06-16	Hoechst Ag	Substituerede benzensulfonylurinstoffer og -thiourinstoffer, fremgangsmåde til deres fremstilling og deres anvendelse som farmaceutika
DE19505397A1 (de) *	1995-02-17	1996-08-22	Hoechst Ag	Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
CN1195524C (zh) *	1998-09-10	2005-04-06	阿文蒂斯药物德国有限公司	苯磺酰(硫)脲与β－受体阻滞剂联合在制备用于心脏迷走神经机能障碍治疗和预防的药物中的用途

1999
- 1999-04-16 DE DE19917233A patent/DE19917233A1/de not_active Withdrawn
2000
- 2000-04-04 DK DK00926805T patent/DK1173418T3/da active
- 2000-04-04 RS YUP-720/01A patent/RS50916B/sr unknown
- 2000-04-04 NZ NZ514788A patent/NZ514788A/xx not_active IP Right Cessation
- 2000-04-04 EP EP05024254A patent/EP1637519B1/en not_active Expired - Lifetime
- 2000-04-04 MX MXPA01010275A patent/MXPA01010275A/es active IP Right Grant
- 2000-04-04 IL IL14592100A patent/IL145921A0/xx active IP Right Grant
- 2000-04-04 DE DE60040811T patent/DE60040811D1/de not_active Expired - Lifetime
- 2000-04-04 BR BR0010658-5A patent/BR0010658A/pt not_active IP Right Cessation
- 2000-04-04 AT AT00926805T patent/ATE311364T1/de active
- 2000-04-04 CA CA002370388A patent/CA2370388C/en not_active Expired - Fee Related
- 2000-04-04 JP JP2000612263A patent/JP4662640B2/ja not_active Expired - Fee Related
- 2000-04-04 PL PL351245A patent/PL203809B1/pl unknown
- 2000-04-04 AU AU45428/00A patent/AU773246B2/en not_active Ceased
- 2000-04-04 WO PCT/EP2000/002984 patent/WO2000063167A1/en active IP Right Grant
- 2000-04-04 TR TR2005/01142T patent/TR200501142T2/xx unknown
- 2000-04-04 TR TR2001/02993T patent/TR200102993T2/xx unknown
- 2000-04-04 ME MEP-557/08A patent/MEP55708A/xx unknown
- 2000-04-04 ES ES00926805T patent/ES2251996T3/es not_active Expired - Lifetime
- 2000-04-04 AT AT05024254T patent/ATE414059T1/de not_active IP Right Cessation
- 2000-04-04 SK SK1458-2001A patent/SK287175B6/sk not_active IP Right Cessation
- 2000-04-04 SI SI200030775T patent/SI1173418T1/sl unknown
- 2000-04-04 EE EEP200100532A patent/EE04612B1/xx not_active IP Right Cessation
- 2000-04-04 DE DE60024431T patent/DE60024431T2/de not_active Expired - Lifetime
- 2000-04-04 KR KR1020017013220A patent/KR100700302B1/ko not_active IP Right Cessation
- 2000-04-04 CZ CZ20013672A patent/CZ302459B6/cs not_active IP Right Cessation
- 2000-04-04 HU HU0200791A patent/HU229082B1/hu not_active IP Right Cessation
- 2000-04-04 EP EP00926805A patent/EP1173418B1/en not_active Expired - Lifetime
- 2000-04-04 CN CNB008063184A patent/CN1168712C/zh not_active Expired - Fee Related
- 2000-04-04 RU RU2001130886/04A patent/RU2235089C2/ru not_active IP Right Cessation
- 2000-04-13 AR ARP000101712A patent/AR023479A1/es not_active Application Discontinuation
- 2000-04-14 US US09/549,538 patent/US6723751B1/en not_active Expired - Lifetime
- 2000-04-14 MY MYPI20001609A patent/MY122588A/en unknown
- 2000-05-10 TW TW089106840A patent/TWI276622B/zh not_active IP Right Cessation
2001
- 2001-10-12 ZA ZA200108400A patent/ZA200108400B/xx unknown
- 2001-10-14 IL IL145921A patent/IL145921A/he not_active IP Right Cessation
- 2001-10-15 NO NO20015014A patent/NO327798B1/no not_active IP Right Cessation
- 2001-10-15 HR HR20010744A patent/HRP20010744B1/xx not_active IP Right Cessation
2002
- 2002-10-30 HK HK02107874.4A patent/HK1046270B/zh not_active IP Right Cessation

Also Published As

Publication number	Publication date
ATE414059T1 (de)	2008-11-15
EP1637519B1 (en)	2008-11-12
BR0010658A (pt)	2002-02-19
KR100700302B1 (ko)	2007-03-29
NO20015014D0 (no)	2001-10-15
HRP20010744A2 (en)	2003-04-30
CZ20013672A3 (cs)	2002-01-16
NZ514788A (en)	2003-03-28
SK287175B6 (sk)	2010-02-08
CZ302459B6 (cs)	2011-06-01
JP4662640B2 (ja)	2011-03-30
JP2002542230A (ja)	2002-12-10
ZA200108400B (en)	2003-04-30
MEP55708A (en)	2011-05-10
CA2370388C (en)	2009-10-13
MXPA01010275A (es)	2003-07-21
IL145921A (he)	2006-07-05
SI1173418T1 (sl)	2006-02-28
CA2370388A1 (en)	2000-10-26
WO2000063167A1 (en)	2000-10-26
DE19917233A1 (de)	2000-10-19
CN1354744A (zh)	2002-06-19
DK1173418T3 (da)	2006-04-10
EP1637519A1 (en)	2006-03-22
HUP0200791A3 (en)	2005-04-28
HU229082B1 (hu)	2013-07-29
KR20010109355A (ko)	2001-12-08
RU2235089C2 (ru)	2004-08-27
HK1046270A1 (en)	2003-01-03
AU4542800A (en)	2000-11-02
TR200501142T2 (tr)	2005-08-22
ATE311364T1 (de)	2005-12-15
YU72001A (sh)	2004-07-15
EE200100532A (et)	2002-12-16
DE60040811D1 (de)	2008-12-24
EP1173418B1 (en)	2005-11-30
RS50916B (sr)	2010-08-31
ES2251996T3 (es)	2006-05-16
EP1173418A1 (en)	2002-01-23
EE04612B1 (et)	2006-04-17
SK14582001A3 (sk)	2002-01-07
IL145921A0 (en)	2002-07-25
DE60024431T2 (de)	2006-07-27
TWI276622B (en)	2007-03-21
NO20015014L (no)	2001-10-15
DE60024431D1 (en)	2006-01-05
AU773246B2 (en)	2004-05-20
PL351245A1 (en)	2003-04-07
CN1168712C (zh)	2004-09-29
MY122588A (en)	2006-04-29
TR200102993T2 (tr)	2002-03-21
US6723751B1 (en)	2004-04-20
HUP0200791A2 (hu)	2002-07-29
AR023479A1 (es)	2002-09-04
HK1046270B (zh)	2005-03-11
PL203809B1 (pl)	2009-11-30
HRP20010744B1 (en)	2010-08-31

Legal Events

Date	Code	Title	Description
2015-11-23	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
CA2116165C (en)	2006-02-21	Substituted benzenesulfonylureas and -thioureas - processes for their preparation and their use as pharmaceuticals
EP1908757A1 (en)	2008-04-09	Choline salt crystal of azulene compound
NO179946B (no)	1996-10-07	Benzoylguanidiner og deres anvendelse som medikamenter
TW383298B (en)	2000-03-01	Amino-substituted benzenesulfonylureas and -thioureas, processes for their preparation, and their use as pharmaceuticals
EP0723956B1 (de)	1999-10-13	Basisch-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
NO329315B1 (no)	2010-09-27	Krystallmodifikasjon av forbindelse, farmasoytiske preparater inneholdende denne og anvendelse av krystallmodifikasjonen.
NO327798B1 (no)	2009-09-28	Krystallinske former av natriumsaltet av 5-klor-2-metoksy-N-(2-(4-metoksy-3-metylaminotio-karbonylamino-sulfonylfenyl)etyl)benzamid, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytiske preparater omfattende disse
CA2138930C (en)	2006-01-17	Substituted benzenesulfonylureas and -thioureas, preparation processes and possible uses of pharmaceutical preparations based on these compounds
CA2169696C (en)	2008-09-02	Substituted benzenesulfonylureas and -thioureas, processes for their preparation and use of pharmaceutical preparations based on these compounds, and medicaments containing them
CZ2001169A3 (en)	2001-05-16	2,5-Substituted benzenesulfonyl ureas and -thioureas, process of their preparation, their use as well as pharmaceutical preparations in which they are comprised
US5631275A (en)	1997-05-20	Substituted benzenesulfonylureas and -thioureas, preparation processes and possible uses of pharmaceutical preparations based on these compounds
CN111303046A (zh)	2020-06-19	含手性羟亚甲基结构的联苯二芳基嘧啶类衍生物及其制备方法和用途
NO140820B (no)	1979-08-13	Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfonylurinstoffderivater